MedTrace Logo

Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma

NCT00377052 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2023-08-04

No results posted yet for this study

Summary

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may help gemcitabine work better by making cancer cells more sensitive to the drug.

PURPOSE: This phase II trial is studying how well giving bortezomib together with gemcitabine works in treating patients with relapsed mantle cell lymphoma.

Conditions

Interventions

DRUG

bortezomib

1.0 mg/m2 IV; injection bolus (3-5 sec) Twice weekly x 2 weeks every three weeks

DRUG

gemcitabine hydrochloride

1000 mg/m2 IV; injection 30 minute infusion Once weekly x 2 weeks every three weeks

Sponsors & Collaborators

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • C. Tom Kouroukis, MD · Margaret and Charles Juravinski Cancer Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-16
Primary Completion
2009-04-21
Completion
2011-06-21

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00377052 on ClinicalTrials.gov